152 related articles for article (PubMed ID: 23805842)
1. Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease.
Pinsetta FR; Taft CA; de Paula da Silva CH
J Biomol Struct Dyn; 2014; 32(7):1047-63. PubMed ID: 23805842
[TBL] [Abstract][Full Text] [Related]
2. Design, crystal structure determination, molecular dynamic simulation and MMGBSA calculations of novel p38-alpha MAPK inhibitors for combating Alzheimer's disease.
Iqbal S; Potharaju R; Naveen S; Lokanath NK; Mohanakrishnan AK; Gunasekaran K
J Biomol Struct Dyn; 2022 Aug; 40(13):6114-6127. PubMed ID: 33522434
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease.
Lee JK; Kim NJ
Molecules; 2017 Aug; 22(8):. PubMed ID: 28767069
[TBL] [Abstract][Full Text] [Related]
4. Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.
Choi H; Park HJ; Shin JC; Ko HS; Lee JK; Lee S; Park H; Hong S
Bioorg Med Chem Lett; 2012 Mar; 22(6):2195-9. PubMed ID: 22342625
[TBL] [Abstract][Full Text] [Related]
5. Identification of p38α MAP kinase inhibitors by pharmacophore based virtual screening.
Gangwal RP; Das NR; Thanki K; Damre MV; Dhoke GV; Sharma SS; Jain S; Sangamwar AT
J Mol Graph Model; 2014 Apr; 49():18-24. PubMed ID: 24473068
[TBL] [Abstract][Full Text] [Related]
6. Azastilbenes: a cut-off to p38 MAPK inhibitors.
Poon JF; Alao JP; Sunnerhagen P; Dinér P
Org Biomol Chem; 2013 Jul; 11(27):4526-36. PubMed ID: 23719673
[TBL] [Abstract][Full Text] [Related]
7. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
8. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of N-cyclopropylbenzamide-benzophenone hybrids as novel and selective p38 mitogen activated protein kinase (MAPK) inhibitors.
Heo J; Shin H; Lee J; Kim T; Inn KS; Kim NJ
Bioorg Med Chem Lett; 2015 Sep; 25(17):3694-8. PubMed ID: 26115577
[TBL] [Abstract][Full Text] [Related]
10. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM
J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
[TBL] [Abstract][Full Text] [Related]
12. Novel strategies for inhibition of the p38 MAPK pathway.
Zhang J; Shen B; Lin A
Trends Pharmacol Sci; 2007 Jun; 28(6):286-95. PubMed ID: 17482683
[TBL] [Abstract][Full Text] [Related]
13. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease.
Munoz L; Ammit AJ
Neuropharmacology; 2010 Mar; 58(3):561-8. PubMed ID: 19951717
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Biological Evaluation of 2,3,4-Triaryl-1,2,4-oxadiazol-5-ones as p38 MAPK Inhibitors.
Romeo R; Giofrè SV; Chiacchio MA; Veltri L; Celesti C; Iannazzo D
Molecules; 2021 Mar; 26(6):. PubMed ID: 33804659
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations.
Chang HW; Chung FS; Yang CN
J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966
[TBL] [Abstract][Full Text] [Related]
16. Syntheses and structure-activity relationships for some triazolyl p38α MAPK inhibitors.
Seerden JP; Leusink-Ionescu G; Leguijt R; Saccavini C; Gelens E; Dros B; Woudenberg-Vrenken T; Molema G; Kamps JA; Kellogg RM
Bioorg Med Chem Lett; 2014 Mar; 24(5):1352-7. PubMed ID: 24508134
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy.
Zhuo ZH; Sun YZ; Jin PN; Li FY; Zhang YL; Wang HL
Mol Biosyst; 2016 Jul; 12(8):2532-40. PubMed ID: 27263470
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
19. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805
[TBL] [Abstract][Full Text] [Related]
20. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening.
Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S
J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]